'Peo­ple want vanil­la ice cream': CEO Anne Wo­j­ci­c­ki grap­ples with 23and­Me's dual iden­ti­ty

SAN FRAN­CIS­CO — 23andMe CEO Anne Wo­j­ci­c­ki said she’s “open to all ideas” in ad­dress­ing in­vestor con­fu­sion and turn­ing around a dis­ap­point­ing start to the ge­nom­ic pi­o­neer’s life as a pub­lic com­pa­ny.

Even as the JP Mor­gan Health­care Con­fer­ence brought a burst of op­ti­mism to start 2024, stoked by a ral­ly­ing biotech mar­ket and im­prov­ing macro­eco­nom­ic cli­mate, 23andMe’s stock dropped an­oth­er 14% last week. The South San Fran­cis­co-based biotech, best known for sell­ing DNA geno­typ­ing kits to mil­lions of peo­ple and now al­so de­vel­op­ing its own drugs, has seen its stock price fall over 90% since go­ing pub­lic in June 2021. It’s tak­en the com­pa­ny’s val­u­a­tion from $3.5 bil­lion at its mar­ket de­but to rough­ly $307 mil­lion. Shares of 23andMe $ME closed Wednes­day at $0.64, an all-time low.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER